Clinical trials in Corbeil Essonnes – page 17

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Corbeil Essonnes at a glance

3 332

clinical trials

Research sites1

Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Interstitial lung disease

Recruiting

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational

France

Participants:0–17 years
Substances:Nerandomilast
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

France

Participants:18–64 years · 65+ years
Substances:Lunsekimig
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:JNJ-79635322
Sponsor:Janssen Cilag International

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Genmab A/S

Contact Research Centre

Neuroblastoma

Recruiting

Study of hu14.18K322A with temozolomide and irinotecan in children and adolescents with high‑risk neuroblastoma

Registered drugNo placebo

Study of hu14.18K322A with temozolomide and irinotecan in children and adolescents with high‑risk neuroblastoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:hu14.18K322A
Sponsor:Renaissance Pharma Limited

Contact Research Centre

Neoplasm+1

Recruiting

Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

Registered drugNo placebo

Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Krystal Biotech Inc.

Contact Research Centre

Systemic lupus erythematosus+3

Recruiting

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Enpatoran hemihydrate
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Small cell lung cancer

Recruiting

Phase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer

Registered drugNo placebo

Phase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Chronic cutaneous lupus erythematosus+2

Recruiting

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational

France

Participants:18–64 years · 65+ years
Substances:Enpatoran hemihydrate
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

Glycemic Control Studies
Cardiovascular Risk Management
Weight Management Therapies

02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

Novel Drug Combinations
Maintenance Therapy Optimization
Minimal Residual Disease Studies

03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

Immunotherapy Development
Alternative Treatment Strategies
Disease Management Protocols

Back to France All countries